CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Regeneron Pharmaceuticals, INC. (REGN) / mibavademab
Forward catalyst · REGN

mibavademab

Sponsor Regeneron Pharmaceuticals, INC. · listed as REGN

READOUT Phase 3 Confidence: medium Source: clinicaltrials

mibavademab is a drug asset sponsored by Regeneron Pharmaceuticals, INC., listed as REGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 18, 2027 (day precision, medium confidence), tied to trial NCT07220772. That trial is in Phase 3 and currently recruiting, studying Monogenic Obesity.

Next catalyst

Event typeREADOUT
Expected date2027-06-18
As disclosedJun 18, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT07220772
PhasePHASE3
StatusRECRUITING
Lead sponsorRegeneron Pharmaceuticals
Listed asREGN
Condition(s)Monogenic Obesity
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More REGN catalysts

Related catalysts and sponsor